CGON: cgoncology.com Price/Earnings to Growth Multiple

Symbol and logo of brand CG Oncology Therapeutics (CGON)

The development of bladder therapy remains independent of economic cycles, as confirmed by the price-to-earnings ratio relative to the EPS growth forecast on the GURU.Markets chart, where 0.00 represents the latest metric reading. CG Oncology, Inc. (CGON) aims for dominance in uro-oncology through large-scale Phase 3 trials, yet the issuer's financial future relies entirely on the success of a single platform.

Price/Earnings to Growth Ratio: CG Oncology Inc (CGON) for 02/21/2024 - 11/16/2026

Analytical breakdowns for CG Oncology Inc (CGON)

General company analysis:CG Oncology, Inc.
Mass-produced product of CG Oncology

Capital efficiency is critical for CG Oncology, Inc. (CGON), as its prospects depend on the commercialization of cancer therapies and R&D expenditures. By analyzing the PEG ratio, an investor compares the current P/E multiple with earnings growth rates: a value below one signals that the asset is undervalued relative to its expansion, allowing the business's growth potential to be identified on this chart.

Who CG Oncology, Inc. competes with

Price/Earnings to Growth Multiple BeiGene Ltd ONC|PEG Multiple HALO (halozyme.com)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|URGN - PEG Multiple|Bicara Bio (BCAX) - Price/Earnings to Growth Ratio|Personalis Corp - Growth-Adjusted Payback Ratio|ERAS (Erasca Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Delcath Systems, Inc. DCTH|Price/Earnings to Growth Multiple YMAB (Y-mAbs Corp)|PEG Multiple Aura Bio (AURA)|PEG Multiple CADL (Candel Therapeutics Inc.)|ARAY - Price/Earnings to Growth Multiple|SLS - Price/Earnings to Growth Ratio|Actuate Therapeutics - Company Value to Earnings Growth Ratio|CTOR: PEG Multiple|TuHURA (HURA) - PEG Multiple|TARA (Protara Therapeutics Inc) - PEG Multiple|FATE: Growth-Adjusted Payback Ratio|PEG Multiple WHWK|TCRX (TScan) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Champions Oncology, Inc. CSBR|XBIT - Price/Earnings to Growth Multiple|CEL-SCI - PEG Multiple|OSTX - PEG Multiple|Radiopharm Theranostics Limited (RADX) - Price/Earnings to Growth Ratio|ARTV - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ANL|Price/Earnings to Growth Ratio VERU|PEG Multiple TPST|XLO: Market Cap to Earnings and Growth Ratio|PEG Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Price to Earnings Adjusted for Growth Rate|Kairos Pharma Ltd - PEG Multiple|Market Cap to Earnings and Growth Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Price/Earnings to Growth Ratio|CRIS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple APLM|Tharimmune (THAR) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ADVB (Advanced Biomed Inc.)|Genprex - Growth-Adjusted P/E Ratio|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Price/Earnings to Growth Multiple|Xenetic Bio - PEG Multiple|SLRX - PEG Multiple|PPBT: PEG Multiple|Growth-Adjusted P/E Ratio AONC|BGNE (BeiGene Ltd) - PEG Multiple|CKPT (Checkpoint Therapeutics, Inc) - Company Value to Earnings Growth Ratio|PEG Multiple ELEV|Price/Earnings to Growth Multiple iCAD Corp ICAD|Price/Earnings to Growth Ratio ikenaoncology.com IKNA|NTBL - Price/Earnings to Growth Multiple|VIRX - Price/Earnings to Growth Ratio|MOR - PEG Multiple|NAYA: PEG Multiple|Ascentage Pharma Group (AAPGV) - PEG Multiple